
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is a biopharmaceutical company with a positive outlook due to their strong track record of producing effective antibodies, with their lead product PEMGARDA showing 84% protective efficacy in their CANOPY trial and their next-generation antibody VYD2311 targeting a much larger population for potential approval by 2027. The company has also received emergency use authorization for PEMGARDA in immunocompromised individuals and has a strong pipeline of potential candidates targeting other viral diseases. Based on current data and management's comments, we believe Invivyd's COVID-19 approaches are superior to mRNA vaccines and could potentially provide longer protection with a single dose. Our valuation, based on a risk-adjusted discounted cash flow model, yields a total firm value of approximately $3 billion or a $10 price target. Risks to our outlook include standard risks in the biopharmaceutical industry, as well as competition, commercialization, reimbursement, and pricing risks for their product candidates.
Bears say
Invivyd is facing a potential roadblock with the termination of its EUA for PEMGARDA by the FDA, as well as the twelve-month transition window for its approval. However, management remains confident in the data for its next-generation antibody candidates and is actively in dialogue to potentially pursue a BLA pathway. The upcoming DECLARATION trial readout for VYD2311 is seen as the main value driver for the company, with management highlighting its strong protection, durability, and low reactogenicity. While payer and policy feedback appear positive, broad access may depend on ACIP/CMS dynamics and the pricing of the expensive prophylactic mAb.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares